CRISPR

-$1.70 (-1.72%) Today

+$0.70 (+0.72%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRISPR and other ETFs, options, and stocks.

About CRSP

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA.

CEO

Samarth Kulkarni

Employees

410

Headquarters

Zug, Zug

Founded

2014

CRSP Key Statistics

Market Cap

7.39B

Price-Earnings Ratio

18.99

Dividend Yield

—

Average Volume

2.32M

High Today

$99.81

Low Today

$96.65

Open Price

$99.23

Volume

1.85M

52 Week High

$220.20

52 Week Low

$84.38

CRSP News

BenzingaOct 13

Why CRISPR Therapeutics Stock Is Tumbling Today

CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refra

MarketWatchOct 13

Crispr's stock is down 5% after sharing early-stage data for its CAR-T therapy candidate

Shares of Crispr Therapeutics Inc. CRSP, +1.93% were down 5.8% in premarket trading on Wednesday, the day after the company announced data from a Phase 1 clinic

Analyst Ratings

72%

of 18 ratings

Buy

72.2%

Hold

22.2%

Sell

5.6%

CRSP Earnings

-$1.51

$2.14

$5.79

$9.44

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Estimated

— per share

Actual

Expected Oct 28, After Hours

Why Robinhood?

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. View more

Why CRISPR Therapeutics Stock Is Tumbling Today

Crispr's stock is down 5% after sharing early-stage data for its CAR-T therapy candidate

72%

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA.